Rene, ADPKD e COVID-19: il doppio ruolo della fragilità renale.
The Corona Virus Disease 19 (COVID19) is an infectious disease caused by SARS – CoV – 2 (Severe Acute Respiratory Syndrome Coronavirus 2). By now, the pandemic has already led 318000 people to their death and our knowledge of this pathogen is still in its infancy. What we know so far is that older patients suffering from different comorbidities, such as heart failure, COPD and tumors, are keener to develop severe complications from which they might perish. The role of chronic kidney disease is still not clear, though. What we do know is that CKD patients are more susceptible to infections, both viral and bacterial, compared to the main population. It has been recently highlighted that the immune response might be the real cause of damage in the lung tissues and not just the virus itself, therefore, the better the immune response, the greater the damage. Quite paradoxically, being chronically renal impaired and suffering from a delayed T-Cell response might actually be beneficial, avoiding a massive inflammatory reaction followed by SARS. According to a recent survey led by the SIN (Italian Society of Nephrology), only 2.8% of COVID patients is under hemodialysis treatment. Unfortunately, we do not have more detailed data on every single specific form of CKD. For instance, there is no clear relation between COVID19 an ADPKD. What might be inferred is the following: COVID uses the ACE2 receptors on cell membranes to “lock on “ its target. It is a well-established fact that the RAAS is more active in ADPKD patients, whether it is a matter of hyper activation or hyper-expression of ACE2 receptors it’s not clear. Also, the fact that these patients are usually on drug treatment with an ACE Inhibitor or an ARB might have some implications that are definitely worth analyzing.
Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 2020;395:1054-62.
Xu Z, Shi L, Wang Y et al. Pathological Findings of COVID-19 Associated With Acute Respiratory Distress Syndrome. The Lancet Respir Med. 2020;8:420-22.
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46: 846-48.
Wang D, Hu B, Hu C. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA;323:1061-69.
Bouadma L, Lescure F-X, Lucet J-C et al. Severe SARS-CoV-2 Infections: Practical Considerations and Management Strategy for Intensivists. Intensive Care Med. 2020;46:579-82.
Xianghong Y, et al. Diagnosis and Treatment of COVID-19: Acute Kidney Injury Cannot Be Ignored. Natl Med J China. 2020;100:1205-8.
Rui W, Liao C, He H et al. COVID-19 in Hemodialysis Patients: A Report of 5 Cases. Am J Kidney Dis. 2020;76:141-3.
Guan WJ, Ni ZY, Hu Y et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708-20.
Zhang Y et al. Vital surveillances: the epidemiological characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (Covid-19) – China CDC Weekly 2020;2:113-122.
Sommerstein R, Kochen M, Messerli FH, Grani C et al. Coronavirus Disease 2019 (COVID‐19): Do Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect? JAHA. 2020 Apr. doi.org/10.1161/JAHA.120.016509.
Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
Stebbing J, Phelan A, Griffin I et al. COVID-19: combining antiviral and anti-inflammatory treatments. The Lancet Infectious Diseases 2020;20:400-402.
Gli autori che scelgono il Giornale di Clinica Nefrologica e Dialisi (GCND) per la pubblicazione dei propri contributi si impegnano ad utilizzare la licenza CC-BY-NC 4.0, che consente a terzi di riutilizzare l'articolo senza richiedere permesso purchè l'articolo sia correttamente citato e non sia utilizzato a scopi commerciali.